Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Background Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A
cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in …

Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population
worldwide. The characteristic white patches result from the selective loss of melanocytes …

Background Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and
reduced quality of life. There is no approved treatment for vitiligo repigmentation and current …

Vitiligo is a common, disfiguring autoimmune disease that negatively affects patients' self-
esteem and quality of life. 1, 2 Existing vitiligo treatments, which are used off-label, are …

Background Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs.
Existing therapies are often inadequate. Prior reports have shown benefit of the Janus …

Vitiligo is an autoimmune cutaneous disease in which melanocytes are destroyed by CD8+
T cells resulting in disfiguring white spots. From the very beginning of the disease, oxidative …

Clinicians should be aware that vitiligo is not merely a cosmetic disease and that there are
safe and effective treatments available for vitiligo. It is important to recognize common and …

Vitiligo is a common autoimmune disease that progressively destroys melanocytes in the
skin, resulting in the appearance of patchy depigmentation. This disfiguring condition …